U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C14H17NO2.ClH
Molecular Weight 267.751
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of INDELOXAZINE HYDROCHLORIDE

SMILES

Cl.C(OC1=C2CC=CC2=CC=C1)C3CNCCO3

InChI

InChIKey=KEBHLNDPKPIPLI-UHFFFAOYSA-N
InChI=1S/C14H17NO2.ClH/c1-3-11-4-2-6-14(13(11)5-1)17-10-12-9-15-7-8-16-12;/h1-4,6,12,15H,5,7-10H2;1H

HIDE SMILES / InChI
Molecular Formula C14H17NO2
Molecular Weight 231.2903
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://pmmp.cnki.net/Resources/CDDPdf/med%5Cbase%5C%E7%A5%9E%E7%BB%8F%E7%B3%BB%E7%BB%9F%E8%8D%AF%E7%89%A9%5C5795.pdf | https://www.ncbi.nlm.nih.gov/pubmed/518676 |https://www.reddit.com/r/Nootropics/comments/17qpe4/indeloxazine_information/

Indeloxazine is a neuroleptic, originally developed and marketed in Japan. It is indicated to allay autonomic hyperactivity following cerebral infarction, cerebral haemorrhage or atherosclerosis. It was found to be a weak inhibitor of both type A and type B monoamine oxidases. Indeloxazine-induced facilitation of acetylcholine release in frontal cortex is mediated by endogenous 5-HT and involves at least in part cortical 5-HT4 receptors. As a potential teratogen, Indeloxazine must not be consumed or handled by pregnant or nursing women, or by women who might become pregnant. It was removed from the market reportedly for lack of effectiveness.

CNS Activity

Originator

Yamanouchi Pharmaceutical
31
Curator's Comment: http://www.chemdrug.com/article/9/3288/16437231.html

Approval Year

2011
587
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 260.0 µM [IC50]
Inhibitor
8297
 90.0 µM [IC50]
Agonist
2678
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Withdrawn
Elen

Approved Use

Indeloxazine was commonly used to treat a psychiatric symptoms, such as memory impairment or emotional disturbance associated with a cerebral infarction, hemorrhage or cerebral arteriosclerosis.
Palliative
Withdrawn
Elen

Approved Use

Indeloxazine was commonly used to treat a psychiatric symptoms, such as memory impairment or emotional disturbance associated with a cerebral infarction, hemorrhage or cerebral arteriosclerosis.
Palliative
Withdrawn
Elen

Approved Use

Indeloxazine was commonly used to treat a psychiatric symptoms, such as memory impairment or emotional disturbance associated with a cerebral infarction, hemorrhage or cerebral arteriosclerosis.
PubMed

PubMed

TitleDatePubMed
Facilitation of acetylcholine release in rat frontal cortex by indeloxazine hydrochloride: involvement of endogenous serotonin and 5-HT4 receptors.
1997 Dec
Neurochemical and behavioral characterization of potential antidepressant properties of indeloxazine hydrochloride.
1998 Sep
Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.
2008 Sep
Patents

Patents

US20100087439
2
US4609656
2

Sample Use Guides

In Vivo Use Guide
20 mg three times daily
Route of Administration: Oral
In Vitro Use Guide
YM-08054-1 at concentrations of less than 1 uM considerably inhibited 5-HT uptake by synaptosomes from rat whole brain as well as noradrenaline (NA) uptake by synaptosomes from rat hippocampus. It blocks the reuptake of noradrenaline with IC50 of 3.2 uM and of serotonin with IC50 of 0.71 uM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:00:11 GMT 2023
Edited
by admin
on Fri Dec 15 15:00:11 GMT 2023
Record UNII
15QZ6NE84E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
INDELOXAZINE HYDROCHLORIDE
JAN   MART.   MI   USAN   WHO-DD  
USAN  
Official Name English
MORPHOLINE, 2-((1H-INDEN-7-YLOXY)METHYL)-, HYDROCHLORIDE, (±)-
Systematic Name English
ELEN
Brand Name English
(±)-2-((INDEN-7-YLOXY)METHYL)MORPHOLINE HYDROCHLORIDE
Systematic Name English
CI-874
Code English
INDELOXAZINE HYDROCHLORIDE [MI]
Common Name English
INDELOXAZINE HYDROCHLORIDE [USAN]
Common Name English
INDELOXAZINE HYDROCHLORIDE [MART.]
Common Name English
YM-08054-1
Code English
INDELOXAZINE HCL
Common Name English
INDELOXAZINE HYDROCHLORIDE [JAN]
Common Name English
Indeloxazine hydrochloride [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C265
Created by admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C81478
Created by admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
PRIMARY
PUBCHEM
47517
Created by admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
PRIMARY
EVMPD
SUB02663MIG
Created by admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
PRIMARY
DAILYMED
15QZ6NE84E
Created by admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
PRIMARY
SMS_ID
100000086982
Created by admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
PRIMARY
EPA CompTox
DTXSID60983582
Created by admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
PRIMARY
MERCK INDEX
m1196
Created by admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL2105022
Created by admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
PRIMARY
FDA UNII
15QZ6NE84E
Created by admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
PRIMARY
RXCUI
1311672
Created by admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
PRIMARY RxNorm
MESH
C020852
Created by admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
PRIMARY
CAS
65043-22-3
Created by admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
PRIMARY
Related Record Type Details
Structure of INDELOXAZINE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of INDELOXAZINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966